BioAtla (BCAB) Competitors

$4.38 -0.32 (-6.81%)

Closing price 04:00 PM Eastern

Extended Trading

$4.44 +0.07 (+1.48%)

As of 04:10 PM Eastern

BCAB vs. SNTI, CELU, AIXC, DYAI, and OTLK

Should you be buying BioAtla stock or one of its competitors? The main competitors of BioAtla include Senti Biosciences (SNTI), Celularity (CELU), Qualigen Therapeutics (AIXC), Dyadic International (DYAI), and Oncobiologics (OTLK). These companies are all part of the "pharmaceutical products" industry.

How does BioAtla compare to Senti Biosciences?

BioAtla (NASDAQ:BCAB) and Senti Biosciences (NASDAQ:SNTI) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, risk, media sentiment, earnings, dividends, analyst recommendations, institutional ownership and valuation.

: BioAtla's return on equity of 0.00% beat Senti Biosciences' return on equity.
Company Net Margins Return on Equity Return on Assets
BioAtla N/A N/A -257.22%
Senti Biosciences N/A -301.48% -90.03%
: BioAtla has higher revenue and earnings than Senti Biosciences. Senti Biosciences is trading at a lower price-to-earnings ratio than BioAtla, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
BioAtla $2M 3.64 -$59.61M -$50.50 N/A
Senti Biosciences $20K 1,485.38 -$61.44M -$3.19 N/A
: In the previous week, Senti Biosciences had 1 more articles in the media than BioAtla. MarketBeat recorded 1 mentions for Senti Biosciences and 0 mentions for BioAtla. BioAtla's average media sentiment score of 0.00 equaled Senti Biosciences'average media sentiment score.
Company Overall Sentiment
BioAtla Neutral
Senti Biosciences Neutral
: BioAtla has a beta of 0.81, meaning that its share price is 19% less volatile than the S&P 500. Comparatively, Senti Biosciences has a beta of 2.09, meaning that its share price is 109% more volatile than the S&P 500.
: 77.2% of BioAtla shares are held by institutional investors. Comparatively, 25.7% of Senti Biosciences shares are held by institutional investors. 11.8% of BioAtla shares are held by insiders. Comparatively, 3.1% of Senti Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
: BioAtla currently has a consensus target price of $200.00, indicating a potential upside of 4,466.21%. Senti Biosciences has a consensus target price of $8.50, indicating a potential upside of 790.99%. Given BioAtla's higher probable upside, analysts clearly believe BioAtla is more favorable than Senti Biosciences.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BioAtla
1 Sell rating(s)
1 Hold rating(s)

1 Buy rating(s)

0 Strong Buy rating(s)
2.00
Senti Biosciences
1 Sell rating(s)

0 Hold rating(s)

3 Buy rating(s)

1 Strong Buy rating(s)
2.80

Company	Net Margins	Return on Equity	Return on Assets
BioAtla	N/A	N/A	-257.22%
Senti Biosciences	N/A	-301.48%	-90.03%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioAtla	$2M	3.64	-$59.61M	-$50.50	N/A
Senti Biosciences	$20K	1,485.38	-$61.44M	-$3.19	N/A

Company	Overall Sentiment
BioAtla	Neutral
Senti Biosciences	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioAtla	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Senti Biosciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

Summary

Senti Biosciences beats BioAtla on 8 of the 15 factors compared between the two stocks.

How does BioAtla compare to Celularity?

Celularity (NASDAQ:CELU) and BioAtla (NASDAQ:BCAB) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, dividends, risk, institutional ownership, valuation, profitability, media sentiment and analyst recommendations.

: In the previous week, Celularity had 2 more articles in the media than BioAtla. MarketBeat recorded 2 mentions for Celularity and 0 mentions for BioAtla. Celularity's average media sentiment score of 0.20 beat BioAtla's score of 0.00 indicating that Celularity is being referred to more favorably in the media.
Company Overall Sentiment
Celularity Neutral
BioAtla Neutral
: Celularity has higher revenue and earnings than BioAtla. Celularity is trading at a lower price-to-earnings ratio than BioAtla, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Celularity $54.22M 0.51 -$57.89M -$3.33 N/A
BioAtla $2M 3.64 -$59.61M -$50.50 N/A
: Celularity currently has a consensus target price of $6.00, suggesting a potential upside of 529.66%. BioAtla has a consensus target price of $200.00, suggesting a potential upside of 4,466.21%. Given BioAtla's higher probable upside, analysts clearly believe BioAtla is more favorable than Celularity.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Celularity
1 Sell rating(s)
0 Hold rating(s)

1 Buy rating(s)

0 Strong Buy rating(s)
2.00
BioAtla
1 Sell rating(s)

1 Hold rating(s)

1 Buy rating(s)

0 Strong Buy rating(s)
2.00
: Celularity has a beta of 0.44, suggesting that its stock price is 56% less volatile than the S&P 500. Comparatively, BioAtla has a beta of 0.81, suggesting that its stock price is 19% less volatile than the S&P 500.
: BioAtla has a net margin of 0.00% compared to Celularity's net margin of -198.75%.
Company Net Margins Return on Equity Return on Assets
Celularity -198.75% N/A -65.03%
BioAtla N/A N/A -257.22%
: 19.0% of Celularity shares are owned by institutional investors. Comparatively, 77.2% of BioAtla shares are owned by institutional investors. 17.3% of Celularity shares are owned by company insiders. Comparatively, 11.8% of BioAtla shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Company	Overall Sentiment
Celularity	Neutral
BioAtla	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Celularity	$54.22M	0.51	-$57.89M	-$3.33	N/A
BioAtla	$2M	3.64	-$59.61M	-$50.50	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Celularity	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
BioAtla	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Company	Net Margins	Return on Equity	Return on Assets
Celularity	-198.75%	N/A	-65.03%
BioAtla	N/A	N/A	-257.22%

Summary

Celularity beats BioAtla on 7 of the 13 factors compared between the two stocks.

How does BioAtla compare to Qualigen Therapeutics?

Qualigen Therapeutics (NASDAQ:AIXC) and BioAtla (NASDAQ:BCAB) are both small-cap pharmaceutical products companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, dividends, risk, institutional ownership, valuation, profitability, media sentiment and analyst recommendations.

: BioAtla has a consensus target price of $200.00, suggesting a potential upside of 4,466.21%. Given BioAtla's stronger consensus rating and higher probable upside, analysts clearly believe BioAtla is more favorable than Qualigen Therapeutics.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Qualigen Therapeutics
1 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
1.00
BioAtla
1 Sell rating(s)

1 Hold rating(s)

1 Buy rating(s)

0 Strong Buy rating(s)
2.00
: Company Net Margins Return on Equity Return on Assets
Qualigen Therapeutics N/A N/A -83.21%
BioAtla N/A N/A -257.22%
: 3.2% of Qualigen Therapeutics shares are owned by institutional investors. Comparatively, 77.2% of BioAtla shares are owned by institutional investors. 1.2% of Qualigen Therapeutics shares are owned by company insiders. Comparatively, 11.8% of BioAtla shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
: In the previous week, Qualigen Therapeutics had 2 more articles in the media than BioAtla. MarketBeat recorded 2 mentions for Qualigen Therapeutics and 0 mentions for BioAtla. Qualigen Therapeutics' average media sentiment score of 0.00 equaled BioAtla'saverage media sentiment score.
Company Overall Sentiment
Qualigen Therapeutics Neutral
BioAtla Neutral
: Qualigen Therapeutics has a beta of 0.52, suggesting that its stock price is 48% less volatile than the S&P 500. Comparatively, BioAtla has a beta of 0.81, suggesting that its stock price is 19% less volatile than the S&P 500.
: Qualigen Therapeutics has higher earnings, but lower revenue than BioAtla. Qualigen Therapeutics is trading at a lower price-to-earnings ratio than BioAtla, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Qualigen Therapeutics N/A N/A -$16.97M -$7.50 N/A
BioAtla $2M 3.64 -$59.61M -$50.50 N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Qualigen Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
BioAtla	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Company	Net Margins	Return on Equity	Return on Assets
Qualigen Therapeutics	N/A	N/A	-83.21%
BioAtla	N/A	N/A	-257.22%

Company	Overall Sentiment
Qualigen Therapeutics	Neutral
BioAtla	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Qualigen Therapeutics	N/A	N/A	-$16.97M	-$7.50	N/A
BioAtla	$2M	3.64	-$59.61M	-$50.50	N/A

Summary

BioAtla beats Qualigen Therapeutics on 8 of the 12 factors compared between the two stocks.

How does BioAtla compare to Dyadic International?

BioAtla (NASDAQ:BCAB) and Dyadic International (NASDAQ:DYAI) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, valuation, risk, institutional ownership, dividends, profitability, media sentiment and analyst recommendations.

: BioAtla has a net margin of 0.00% compared to Dyadic International's net margin of -239.67%. BioAtla's return on equity of 0.00% beat Dyadic International's return on equity.
Company Net Margins Return on Equity Return on Assets
BioAtla N/A N/A -257.22%
Dyadic International -239.67% -695.96% -78.24%
: BioAtla presently has a consensus price target of $200.00, suggesting a potential upside of 4,466.21%. Dyadic International has a consensus price target of $3.00, suggesting a potential upside of 289.56%. Given BioAtla's higher possible upside, analysts plainly believe BioAtla is more favorable than Dyadic International.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BioAtla
1 Sell rating(s)
1 Hold rating(s)

1 Buy rating(s)

0 Strong Buy rating(s)
2.00
Dyadic International
1 Sell rating(s)

0 Hold rating(s)

2 Buy rating(s)

0 Strong Buy rating(s)
2.33
: In the previous week, Dyadic International had 2 more articles in the media than BioAtla. MarketBeat recorded 2 mentions for Dyadic International and 0 mentions for BioAtla. BioAtla's average media sentiment score of 0.00 equaled Dyadic International'saverage media sentiment score.
Company Overall Sentiment
BioAtla Neutral
Dyadic International Neutral
: Dyadic International has higher revenue and earnings than BioAtla. Dyadic International is trading at a lower price-to-earnings ratio than BioAtla, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
BioAtla $2M 3.64 -$59.61M -$50.50 N/A
Dyadic International $3.09M 9.08 -$7.36M -$0.25 N/A
: BioAtla has a beta of 0.81, suggesting that its share price is 19% less volatile than the S&P 500. Comparatively, Dyadic International has a beta of 1.18, suggesting that its share price is 18% more volatile than the S&P 500.
: 77.2% of BioAtla shares are owned by institutional investors. Comparatively, 28.0% of Dyadic International shares are owned by institutional investors. 11.8% of BioAtla shares are owned by company insiders. Comparatively, 29.5% of Dyadic International shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Company	Net Margins	Return on Equity	Return on Assets
BioAtla	N/A	N/A	-257.22%
Dyadic International	-239.67%	-695.96%	-78.24%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioAtla	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Dyadic International	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Company	Overall Sentiment
BioAtla	Neutral
Dyadic International	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioAtla	$2M	3.64	-$59.61M	-$50.50	N/A
Dyadic International	$3.09M	9.08	-$7.36M	-$0.25	N/A

Summary

Dyadic International beats BioAtla on 10 of the 15 factors compared between the two stocks.

How does BioAtla compare to Oncobiologics?

Oncobiologics (NASDAQ:OTLK) and BioAtla (NASDAQ:BCAB) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, media sentiment, risk, institutional ownership, valuation, dividends, earnings and analyst recommendations.

: Company Net Margins Return on Equity Return on Assets
Oncobiologics N/A N/A -293.47%
BioAtla N/A N/A -257.22%
: 11.2% of Oncobiologics shares are held by institutional investors. Comparatively, 77.2% of BioAtla shares are held by institutional investors. 2.8% of Oncobiologics shares are held by insiders. Comparatively, 11.8% of BioAtla shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
: Oncobiologics currently has a consensus price target of $4.50, suggesting a potential upside of 1,761.81%. BioAtla has a consensus price target of $200.00, suggesting a potential upside of 4,466.21%. Given BioAtla's higher probable upside, analysts plainly believe BioAtla is more favorable than Oncobiologics.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Oncobiologics
1 Sell rating(s)
4 Hold rating(s)

1 Buy rating(s)

0 Strong Buy rating(s)
2.00
BioAtla
1 Sell rating(s)

1 Hold rating(s)

1 Buy rating(s)

0 Strong Buy rating(s)
2.00
: In the previous week, Oncobiologics had 4 more articles in the media than BioAtla. MarketBeat recorded 4 mentions for Oncobiologics and 0 mentions for BioAtla. Oncobiologics' average media sentiment score of 1.00 beat BioAtla's score of 0.00 indicating that Oncobiologics is being referred to more favorably in the media.
Company Overall Sentiment
Oncobiologics Positive
BioAtla Neutral
: BioAtla has higher revenue and earnings than Oncobiologics. Oncobiologics is trading at a lower price-to-earnings ratio than BioAtla, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Oncobiologics $205.70K 122.92 -$62.42M -$2.62 N/A
BioAtla $2M 3.64 -$59.61M -$50.50 N/A
: Oncobiologics has a beta of 0.32, suggesting that its stock price is 68% less volatile than the S&P 500. Comparatively, BioAtla has a beta of 0.81, suggesting that its stock price is 19% less volatile than the S&P 500.

Company	Net Margins	Return on Equity	Return on Assets
Oncobiologics	N/A	N/A	-293.47%
BioAtla	N/A	N/A	-257.22%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oncobiologics	1 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
BioAtla	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Company	Overall Sentiment
Oncobiologics	Positive
BioAtla	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oncobiologics	$205.70K	122.92	-$62.42M	-$2.62	N/A
BioAtla	$2M	3.64	-$59.61M	-$50.50	N/A

Summary

BioAtla beats Oncobiologics on 8 of the 12 factors compared between the two stocks.

Get BioAtla News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BCAB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BCAB vs. The Competition

Export

Metric	BioAtla	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$7.27M	$3.39B	$6.25B	$11.87B
Dividend Yield	N/A	2.20%	2.73%	5.21%
P/E Ratio	-0.09	38.92	29.03	28.47
Price / Sales	3.64	154.75	476.10	60.92
Price / Cash	N/A	57.88	27.62	36.52
Price / Book	-0.15	7.03	9.67	6.67
Net Income	-$59.61M	$23.62M	$3.55B	$332.53M
7 Day Performance	1.86%	3.78%	1.75%	2.03%
1 Month Performance	-32.82%	7.30%	5.66%	9.23%
1 Year Performance	-83.08%	67.15%	34.42%	39.62%

BioAtla Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BCAB BioAtla	1.5966 of 5 stars	$4.38 -6.8%	$200.00 +4,466.2%	N/A	$7.27M	$2M	N/A	60	Positive News Upcoming Earnings
SNTI Senti Biosciences	2.5799 of 5 stars	$0.96 -9.2%	$8.50 +783.6%	N/A	$29.96M	$22K	N/A	4
CELU Celularity	1.6052 of 5 stars	$1.03 +4.1%	$6.00 +482.0%	N/A	$29.73M	$54.22M	N/A	220	Earnings Report Upcoming Earnings
AIXC Qualigen Therapeutics	0.0075 of 5 stars	$1.46 -4.6%	N/A	N/A	$29.53M	N/A	N/A	50	Gap Up
DYAI Dyadic International	2.1077 of 5 stars	$0.81 -1.2%	$3.00 +270.4%	N/A	$29.52M	$1.23M	N/A	7

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BCAB) was last updated on 5/5/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

BioAtla (BCAB) Competitors

BCAB vs. SNTI, CELU, AIXC, DYAI, and OTLK

How does BioAtla compare to Senti Biosciences?

Summary

How does BioAtla compare to Celularity?

Summary

How does BioAtla compare to Qualigen Therapeutics?

Summary

How does BioAtla compare to Dyadic International?

Summary

How does BioAtla compare to Oncobiologics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BCAB vs. The Competition

BioAtla Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

BioAtla (BCAB) Competitors

BCAB vs. SNTI, CELU, AIXC, DYAI, and OTLK

How does BioAtla compare to Senti Biosciences?

Summary

How does BioAtla compare to Celularity?

Summary

How does BioAtla compare to Qualigen Therapeutics?

Summary

How does BioAtla compare to Dyadic International?

Summary

How does BioAtla compare to Oncobiologics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BCAB vs. The Competition

BioAtla Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools